Heart drug acoramidis tested for Long-Term cardiac repair in rare amyloidosis
Disease control
Not yet recruiting
This study tests the drug acoramidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal proteins build up in the heart, weakening it. Over 36 months, researchers measure whether acoramidis improves heart function and structure using cardiac …
Phase: PHASE4 • Sponsor: Eidos Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC